429
Participants
Start Date
May 14, 2019
Primary Completion Date
April 1, 2025
Study Completion Date
February 28, 2026
Acasunlimab
Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
Acasunlimab in combination with docetaxel (in a single expansion cohort)
Acasunlimab and docetaxel will be administered intravenously once every 21 days.
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
IOB-Hospital Quironsalud Barcelona, Barcelona
NYU Langone, New York
Hadassah Medical Organization HMO - Sharett Institute of Oncology, Jerusalem
UNC Chapel Hill, Chapel Hill
START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
START Madrid-CIOCC, Madrid
Levine Cancer Institute, Atrium Health, Charlotte
NEXT Oncology Madrid, Madrid
Emory University, Atlanta
Clinica Universidad de Navarra, Pamplona
Mayo Clinic, Jacksonville
Norton Healthcare Inc, Louisville
University Hospitals Cleveland Medical Center, Cleveland
Hospital Clinico De Valencia, Valencia
University of Michigan, Ann Arbor
START Midwest, Grand Rapids
University of Iowa Hospitals, Iowa City
Sheba Medical Center, Ramat Gan, Tel Litwinsky
Mayo Clinic, Rochester
Washington University School of Medicine, St Louis
Tel Aviv Sourasky Medical Center, Tel Aviv
Mayo Clinic, Phoenix
Yale University Cancer Center, New Haven
Fakultni nemocnice Brno, Brno
University Hospital Brno, Brno
Nemocnice AGEL Ostrava-Vítkovice a.s., Nový Jičín
Fakultni nemocnice Olomouc, Olomouc
High Technology Hospital Medcenter, Batumi
"LLC TIM - Tbilisi Institute of Medicine", Tbilisi
LTD Consilium Medulla, Tbilisi
Tbilisi State Medical University and Ingorovka High Medical Technology University Clinic Ltd, Tbilisi
Onkologiai Klinika, Debrecen
BKMK Hospital, Kecskemét
Pulmonology Hospital Törökbálinti, Törökbálint
Rambam Health Care Campus RHCC - Rambam Medical Center, Haifa
Policlinico San'Orsola, Bologna
IRCCS - Istituto Europeo di Oncologia IEO, Milan
Istituto Nazionale Tumori - Fondazione Pascale Italy, Napoli
Azienda Ospedaliero Universitaria di Parma, Parma
AUSL Romagno-Ravenna, Ravenna
Policlinico Uni. Campus Bio-Medico, Roma
Regina Elena National Cancer Institute, Rome
"ASST Sette Laghi Ospedale di Circolo e Fondazione Macchi ", Varese
Uniwersyteckie Centrum Kliniczne, Gdansk
Medpolonia Sp. z o.o., Poznan
Specialist Hospital in Prabuty, Prabuty
Dom Lekarski SA, Szczecin
Maria Sklodowska Curie National Research Instutute of Oncology, Warsaw
Hospital Universitario La Princesa, Madrid
MD Anderson Cancer Center Madrid, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
Gulhane Training and Research Hospital, Ankara
Trakya University Hospital, Edirne
Medical Point Izmir Hospital, Karşıyaka
ARENSIA Exploratory Medicine LLC, Kyiv
Hospital Universitario Vall dHebron, Barcelona
Lead Sponsor
Genmab
INDUSTRY